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Abstract 
Background Our hospital experienced an outbreak of OXA-48-producing Enterobacteriaceae, 
triggering this study. We aimed to describe the population with carbapenemase-producing 
Enterobacteriaceae (CPE) in our hospital from 2014 to 2018, the phenotypic and genotypic 
characteristics of isolates, and strategies to stop the outbreak. 
Methods We performed a retrospective study, including every patient with CPE species in a clinical 
sample. Epidemiology, risk factors, treatment and outcomes were gathered from medical records. 
Results A total 113 patients were included, ranging from 5 in 2015 to 83 in 2018. In 2018 the 
number of CPE went from 4 in May to 20 in July. With the implemented measures, propagation 
stopped. Implantable devices were present in 36% of patients and open wounds in 34%. Antibiotics had 
been prescribed to 71% of patients in the prior 30 days and most of the patients had been hospitalized 
for more than 5 days prior to sample collection or had a hospital stay in the previous year.  
Klebsiella pneumoniae was the most common species (87%). OXA-48 (62%) and Klebsiella 
pneumoniae-carbapenemase (KPC) (15%) were the most common carbapenemases, with OXA-48 being 
implicated in the 2018 outbreak. The case fatality rate at 30 days was 32%. Combination therapy 
resulted in less mortality. 
Conclusions While KPC is the most common carbapenemase in Europe and Portugal, we 
experienced an important OXA-48 outbreak. Surveillance should be in place as these isolates are 
probably spreading. Effective communication, multidisciplinary team work and proper infection control 
measures are some of the best strategies during outbreaks. 
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Introduction 
Ever since the first steps in antibiotic 
treatment, there has been emergence of 
resistances alongside new treatment discoveries.1 
Enterobacteriaceae like Escherichia coli, 
Klebsiella pneumoniae and Enterobacter are some of 
the most common causes of community- and 
healthcare-associated infections.2-4 The 
development of extended spectrum beta-
lactamases (ESBL), plasmid-mediated Amp1 
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enzymes and deficiency of porins in the outer 
membrane, has led to important resistances to 
beta-lactams.5,6 Therefore, carbapenems currently 
play a critically important role. However, in the 
last two decades, we have watched the emergence 
and spread of carbapenemase-producing 
Enterobacteriaceae (CPE) worldwide, with few 
antibiotics remaining active.7,8 These multidrug-
resistant Enterobacteriaceae have a significant 
impact on multiple sectors: they cause millions of 
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deaths annually, are more difficult to treat, 
require longer treatment duration and increase 
in-hospital length of stay, with great repercussion 
on healthcare costs.9,10 
K. pneumoniae in particular has been regarded 
as a critical priority across the globe for its 
growing expansion of carbapenem resistance, 
being listed as a top threat by WHO.11-13 In 
Europe, K. pneumoniae carbapenemase (KPC) is 
the most common carbapenemase, with ongoing 
transmission across the continent.12 
Mediterranean countries, namely Turkey, Greece 
and Spain, have first witnessed the rise of OXA-
48-producing isolates but these currently have a 
global distribution.12,14 Portugal still lacks detailed 
and updated information on its situation 
regarding CPE. Reports from 2014 listed KPC-
positive K. pneumoniae as the most frequent CPE, 
but OXA-48-producing species have been 
described in some local reports.15-17 
Colistin and tigecycline remain some of the 
most important therapeutic options in CPE 
infections but their efficacy (even in combination 
with other agents) is uncertain and resistance is 
also a threat, leaving us with few therapeutic 
options.18-21 New agents such as ceftazidime-
avibactam, ceftolozane-tazobactam, meropenem-
vaborbactam and plazomicin have been 
developed and are promising but rational use 
must remain key.22 
We describe the CPE epidemiology in a 
Portuguese regional hospital. During the year of 
2018 a largely growing number of CPE isolates 
was detected while previously they occurred only 
sporadically. This raised suspicion of nosocomial 
transmission and triggered our Infection Control 
Committee to reinforce infection control 
measures. In this context, we initiated a 
retrospective analysis of patient epidemiology, 
microbiology and resistance data, clinical 
measures taken and outcomes. Here we describe 
the findings of a five-year retrospective analysis. 
 
Methods 
Patients and setting 
This study was conducted in a regional 
hospital, located in Cascais, Portugal, which 
comprises 277 beds for acute care, an 18-bed 
ICU and Emergency Care, and provides care for 
adult and pediatric patients from a population 
of 211,302 people. A retrospective analysis of 
CPE isolates between 2015 and 2018 was made, 
based on the records of our Microbiology 
Laboratory and our Infection Control 
Committee. We included every clinical sample 
analyzed in the microbiology laboratory, whether 
it was from patients in the Emergency Room, 
outpatient or inpatient care. For each patient, 
we only included the first isolate, since multiple 
patients became colonized and had subsequent 
CPE-positive clinical samples. In July 2018, we 
implemented rectal swab screenings for CPE and 
patients with positive screenings for CPE were 
also included. This screening depended on the 
physician decision but was recommend in 
patients with multiple antibiotic cycles in the 
previous year, institutionalized in nursing-
homes, hospitalized in the previous year or who 
had contact with a patient with CPE.  
 
Microbiology sample analysis 
Regarding microbiologic methods, samples 
prior to 2018 were sent to the Portuguese 
National Health Institute that would later 
inform us on carbapenemase identification. The 
Institute used disk diffusion to analyze 
antimicrobial susceptibility, according to 
EUCAST guidelines. Clinical isolates with 
resistance or decreased susceptibility to 
ertapenem were submitted to PCR and 
sequencing to detect and identify CPE and 
ESBL-encoding genes.  
In our microbiology laboratory, Vitek 
MS/Vitek 2 (bioMe ́rieux, Marcy-l’Étoile, France) 
was used for automated bacterial identification 
and antibiotic susceptibility testing. Each sample 
with a minimal inhibitory concentration (MIC) 
by E-TEST (bioMérieux), corresponding to 
intermediate susceptibility or resistance to any 
carbapenem (according to EUCAST criteria) was 
tested for carbapenemase production with a 
immunochromatography test from Coris (Coris, 
Genbloux, Belgium).  
The rectal screening samples were inoculated 
in Brilliance CRE Agar (Oxoid, Cheshire, 
England), a chromogenic screening plate for 
CPE, and positive results went through VITEK-
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MS for automated mass spectrometry microbial 
identification. 
In July of 2018, regarding the possibility of a 
nosocomial outbreak of CPE, more strict 
infection control measures were implemented in 
order to stop transmission. 
 
Results  
Between 2015 and 2018, CPE were detected 
in a total of 113 patients. Of these 113, nine 
were diagnosed after being selected for CPE 
screening with rectal sample. The clinicians 
ordered a total of 91 screening tests (nine 
positive, 10%). The number of isolates per year 
ranged from 5 in 2015 to 83 in 2018. 
Patients were considered colonized if they 
had CPE isolates on clinical samples but showed 
no signs of active infection (fever, elevated 
inflammatory markers, clinical symptoms related 
with infection, etc.), according to the clinician 
best judgement. Seventy-two patients (64%) were 
considered infected and the remaining 
colonized. 
We only had two OXA-48 isolates before 
2018. From May 2018 an outbreak was 
suspected (see Figure 1). 
 
 
Figure 1. Number of total CPE isolates per 
month in 2018 (dots) and number of OXA-48 
isolates per month in 2018 (full line) 
 
Characteristics of patients 
The incidence of infection/colonization with 
CPE was higher in males (57%). The average age 
was 75.6 years (range 0-100 years), with 47% 
being 80 or older. Sixty-six percent of the 
patients lived at home while 31% were 
institutionalized (nursing home or rehabilitation 
center). One of our patients was a preterm 
neonate born at our hospital.  
The main causes of admission were urinary 
tract infection (UTI) (31%), respiratory tract 
infection (17%) and diabetic foot infection 
(8%). Other less common causes of admission 
were heart disease, abdominal infections, 
oncologic problems, skin infections, amongst 
others. 
Medical devices such as urinary catheters, 
central venous catheters, tracheostomy tubes, 
chest tubes; or invasive procedures such as 
mechanical ventilation, recently implanted hip 
prosthesis or endourological procedures, were 
present in 36% of our patients. Urinary 
catheters were present, or had been for more 
than two days in the same hospitalization, in 
25% of the patients, being the most frequent 
device. Open wounds such as pressure ulcers, 
postoperative wounds or even burns were 
present in 33.6% of patients. 
Seventy-one percent of the patients had taken 
antibiotics in the 30 days preceding the CPE 
diagnosis and 58% of those had two or more 
antibiotic courses. The antibiotic classes most 
prescribed were penicillins (60%), third-
generation cephalosporins (20%), carbapenems 
(19%) and vancomycin (10%). Most of the 
patients (88%) had been hospitalized for more 
than five days prior to the sample collection or 




The infection site most affected was the 
urinary tract, in 69% (n=78) of the patients and 
8% (n=6) of these also had bacteremia. The 
sputum was positive in 9% (n=10) (10% of these 
with bacteremia), wound exudates/surgical 
aspirates in 6% (n=7), ascitic fluid in 1% (n=1) 
and 8% (n=9) of the patients had isolated 
bacteremia.  
Eighty-seven percent (n=90) of the isolates 
from were K. pneumoniae (Table 1), 10% 
Enterobacter cloacae, 3% E. coli and only one 
isolate was Citrobacter freundii. There was no E. 
coli with carbapenemase activity before 2017. 
The nine screenings for CPE corresponded to K. 
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pneumoniae isolates but we have no further 
details from antibiotic susceptibility and will 
further describe the results from the 104 isolates 
from other clinical samples.  
 
Table 1. Number of isolates (percentage) for 
each species 
 
Species isolated Number of isolates (%) 
K. pneumoniae 90 (87%) 
Enterobacter cloacae 10 (10%) 
E. coli 3 (3%) 
Citrobacter freundii 1 (1%) 





OXA-48 was the most common 
carbapenemase, found in 62% (n=64) of our 
isolates, followed by KPC, present in 15% 
(n=16) (Table 2).  
 
Table 2. Number of isolates (percentage) for 
each resistance mechanism 
 
Resistance mechanism Number of isolates (%) 
OXA 48 64 (62%) 
KPC 15 (14%) 
MBL 2 (2%) 
MBL + AmpC 2 (2%) 
KPC + MBL 1 (1%) 
Unknown or inconclusive 20 (19%) 
TOTAL 104 (100%) 
 
Co-production of ESBL was present in 63% 
of the total of CPE isolates and in 81% of the 
OXA 48 isolates.  
From the 104 CPE isolates, 13% had 
intermediate susceptibility and 88% were 
resistant to ertapenem. Regarding meropenem, 
74% were susceptible, 5% had intermediate 
susceptibility and 21% were resistant.  
From the OXA-48 producers only 6% (n=4) 
of the isolates had a meropenem MIC >8 mg/L, 
while in the KPC group this happened in 31% 
(n=5) (but we did not have access to the 
meropenem MIC of 19% of the KPC isolates). 
From the OXA-48 isolates, 89% had an 
ertapenem MIC >1 mg/L but the vast majority 
remained susceptible to meropenem: 94% 
(n=60) had a meropenem MIC ≤2 mg/L and 
only 6% (n=4) had a meropenem MIC >2 mg/L 
(one with MIC 16 mg/L and three with MIC 32 
mg/L). 
Resistance to colistin was present in only one 
of the isolates (K. pneumoniae with AmpC 
enzyme and ESBL-positive with intermediate 
susceptibility to ertapenem, that maintained 
susceptibility to meropenem with MIC<2).  
 
Treatment and outcomes 
Ninety-one percent (n=103) of our patients 
required in-hospital care whether because of 
clinical instability or for the need of intravenous 
antibiotic treatment. The average hospital stay 
was 20 days, being longer in patients considered 
infected than in colonized ones (27 days vs. 13.5 
days). 
Susceptibility-guided treatment was only 
possible for 75% of patients with infection (total 
of 54 treatments). This happened mainly 
because patients died before the antimicrobial 
susceptibility was available.  
The case fatality rate (that we considered at 
30 days after the first CPE detection, for any 
cause of death) was 32% (n=36) in the global 
population of CPE infected/colonized, 41% in 
those considered infected and 17% in those 
colonized (Table 3).  
Table 3. Case fatality rate depending on 
infected or colonized status 
 
Status Case fatality rate 
Global study population 32% 
Patients considered infected 41% 
Patients considered colonized 17% 
Patients with OXA-48 isolates 28% 
Patients with KPC isolates 25% 
 
The case fatality rate was 28% in the patients 
with OXA-48 isolates and 25% in the KPC 
group. In the OXA-48 group we had 41 patients 
considered infected and 23 colonized with the 
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case fatality rate being 39% in the infected and 
9% in the colonized. In the KPC group we had 
ten patients infected and six colonized with the 
case fatality rate being 40% in the infected and 
0% in the colonized patients. 
From the patients considered infected, those 
who had guided antibiotic had a lower case 
fatality rate of 25%. 
Regarding treatment, from the 54 cases in 
which susceptibility was available, the adequate 
treatment was only implemented in 52 patients. 
In the two cases in which the treatment regimen 
was not adequate, one included meropenem 
alone, even though the MIC was >8 mg/L, and 
in one case an aminoglycoside alone was used. 
Only 32 patients received combination 
treatment. Mortality rate was inferior in patients 
with adequate antimicrobial regimen and even 
more if the treatment regimen included two or 
more antibiotic classes (Table 4). 
Table 4. Adequacy of treatment regimen 










52 96% 25.0% 
Combined treatment 32 61.5% 18.8% 
Not combined 
treatment 
20 38.5% 35.0% 
Not adequate  2 4% 50% 
 
Single agent antibiotic treatment was used in 
cases with meropenem MIC <2 or in cases 
before 2017 and the main agents were 
meropenem, ceftazidime-avibactam or colistin.  
Included in the monotherapy group were five 
patients treated exclusively with ceftazidime-
avibactam with no deaths registered. Amongst 
patients treated with only meropenem or only 
amikacin, the case fatality rate was 45%. 
The treatment most used was meropenem 
with amikacin, in 11 patients, mainly patients 
with K. pneumoniae OXA 48 with ESBL 
production (Table 5). Two patients treated this 
way died. Meropenem with colistin was used in 
nine patients, with two deaths in the 30 days 
after the detection of CPE. 
Meropenem monotherapy was used in nine 
patients, six with UTI and three with CPE 
isolates on blood samples, mainly before 2018. It 
was used in seven K. pneumoniae that were 
resistant to ertapenem but susceptible to 
meropenem. Three of these patients died. It was 
also used in one Enterobacter cloacae resistant to 
ertapenem but susceptible to meropenem and in 
one E. coli OXA-48 and ESBL-positive, with no 
mortality at 30 days.  
Ceftazidime-avibactam became available at 
our hospital in July 2018, and we used it to treat 
four K. pneumoniae OXA 48 and one KPC with 
good results and no mortality at 30 days. 
Another patient was considered colonized with 
OXA-48 K. pneumoniae and MRSA but 
afterwards became ill and was treated with 
ceftazidime-avibactam and linezolid and did not 
die during the 30 day-period after the screening 
test but died before ending antibiotic treatment. 
Another patient with diabetic foot ulcer 
infection with K. pneumoniae OXA 48 was 
treated with amikacin plus colistin plus 
ceftazidime-avibactam with success.  
Treatment with colistin alone was used in 
four patients, one with Citrobacter freundii with 
KPC production, one with K. pneumoniae with 
KPC, one with Enterobacter cloacae with VIM and 
AmpC and one with K. pneumoniae with 
resistance to meropenem and ertapenem in 
which we did not have the carbapenemase 
identification. All of the four patients died 
within 30 days. Colistin in combination therapy 
was used with success with ampicillin, tigecycline 
and gentamicin respectively, in three patients. 
One patient with K. pneumoniae OXA 48 
maintained susceptibility to ciprofloxacin and 
was treated accordingly with success. 
 
Discussion 
Carbapenemases are proliferating worldwide 
and Portugal is not an exception.13  
While our hospital has registered a relevant 
increase in CPE numbers in 2018, this was 
integrated in a nosocomial outbreak with 
numbers returning close to the pre-outbreak 
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incidence. A continuous surveillance and 
infection control strategy should be in place to  
understand how these numbers evolve 
throughout the years. During this outbreak, our 
healthcare workers were intensively re-educated 
on infection control measures. Between July and 
September 2018, patients with CPE 
infection/colonization were isolated in a cohort 
with a specific team of healthcare workers 
assigned exclusively to them. An online 
communication group was formed between the 
microbiology laboratory, the cohort task force 
and the team responsible for bed-occupancy 
management, so that patients with CPE isolates 
were isolated as fast as possible. Patients and 
families were also educated on infection control 
measures and instructed to warn the hospital 
staff, in subsequent hospital visits, of their 
previous infection/colonization with CPE. 
Effective communication and (multidisciplinary) 
team work, with mandatory and fast reports, were 
some of the most important features of our 
experience towards outbreak control. This goes in 
hand with previous studies that highlight the 
interdisciplinary team importance in infection 
control.23 
As we describe an outbreak with nosocomial 
transmission, it would be highly relevant to 
analyze risk factors inherent to in-hospital 
transmission such as ward distribution, staying in 
single-bed rooms vs. in multiple-bed rooms, or 
even common nursing staff but, retrospectively, 
that information was not available. The most 
relevant patient characteristics, that may point to 
risk factors of CPE infection, were age, open 
wounds, medical devices, prior antibiotic use (in 
the previous 30 days), especially if two or more 
antibiotic courses and hospitalization in the 
previous 12 months. Medical devices have been 
largely known as a risk factors for acquiring CPE 
and are, at times, avoidable.24 Reducing 
unnecessary devices is essential to patient safety, 
particularly regarding urinary catheters which 
played a significant role in our study. Urinary 







Meropenem + amikacin 11 2 18% 
Meropenem + colistin 9 2 22% 
Meropenem 9 3 25% 
Ceftazidime-avibactam 5 0 0% 
Colistin 4 4 100% 
Tigecycline + colistin 3 1 33% 
Amikacins + colistin 2 1 50% 
Meropenem + gentamicin 2 0 0% 
Tigecycline + piperacillin/tazobactam + clindamycin 1 Unknown Unknown 
Meropenem + ceftazidime 1 1 100% 
Amikacin + colistin + ceftazidime-avibactam 1 0 0% 
Ceftazidime-avibactam + linezolid 1 0 0% 
Colistin + ampicillin 1 0 0% 
Colistin + tigecycline 1 0 0% 
Colistin + gentamicin 1 0 0% 
Gentamicin + cefotaxime 1 0 0% 
Ciprofloxacin 1 0 0% 
Unknown 1 0 0% 
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catheters must be carefully considered before 
their placement and their utility should be 
reassessed daily.14,25 Open wounds, namely 
surgical wounds and pressure ulcers, were of 
utmost relevance. Being associated with severe 
illness, they probably also represent increased 
susceptibility to infection. Wound care should be 
carefully managed regarding infection control 
measures and early detection of these isolates on 
surgical wards and antibiotic stewardship 
measures are crucial.  
OXA-48 was the most frequently detected 
carbapenemase but the vast majority of these 
isolates had ESBL co-production. Since OXA-48 
carbapenemases in isolation induce no hydrolysis 
of cephalosporins and only weak hydrolysis of 
carbapenems, the co-production of other beta-
lactamases made their identification more 
evident.14 There is probably a larger population of 
OXA-48 isolates that goes undetected and may be 
spreading. KPC is still the most common 
carbapenemase in Portugal and our study is the 
first describing an OXA-48 outbreak and the first 
Portuguese Hospital with OXA 48 
predominance.12,16 
The fact that OXA-48 isolates, in the vast 
majority, maintained meropenem MIC inferior 
to 8 allowed us to keep it in our therapeutic 
options. Colistin resistance in Enterobacteriaceae 
is still very infrequent but reports have been 
spreading.19 Until the end of 2018 we only had 
one case of colistin resistance. 
Community acquired carbapenemases are also 
worrisome, even more because most 
Enterobacteriaceae are very common in the 
community.14 Most of our patients (88%) had 
nosocomial infection or had a prior admission to 
the hospital within the prior 12 months. It is our 
belief that these carbapenemases were mainly 
hospital-acquired but studies regarding the 
prevalence of these resistances in the community 
are lacking. K. pneumoniae was by far the most 
common species with carbapenemase production, 
which was expected giving the international 
results.26 E. coli with carbapenemase activity is still 
infrequent but, while it was never detected before 
2017 at hour hospital, in 2018 we had two 
cases.26 Spreading of carbapenem-resistant E. coli 
in the community may lead to the emergence of 
untreatable community-acquired infections. 
The global case fatality rate at 30 days of 32% 
is in accordance with other studies.27,28 Even 
though colonized patients had a lower case 
fatality rate of 17% (vs. 41% in infected), this is 
still considerable. It is difficult to compare to 
other studies since the definition of colonization 
vs infection is not uniform. Another limitation to 
our study is that we did not analyze the 
proportion of patients considered colonized that 
went on to develop infections and this would be 
an area for future work. 
Regarding treatment, we acknowledge our 
high portion of patients treated with 
monotherapy which is not the most advisable 
strategy.7 One explanation is that, in the majority 
of the cases, those were strains that remained 
susceptible to meropenem with MIC <2 and 
monotherapy with meropenem was implemented. 
However, our study, with its limitations and 
small number of treated patients, points to better 
results with combination therapy. 
We acknowledge that this study has numerous 
limitations, namely having a rather high 
proportion of isolates in which phenotypically 
there was resistance to carbapenems but in which 
no carbapenemase was identified. This happened 
mainly before 2017 and is a consequence of the 
previous centralization of microbiologic analysis 
and poor communication between institutions. It 
is also an exclusively descriptive report but we 
highlight the importance of tight infection 
control measures on the termination of a 
nosocomial outbreak of CPE. Case-control 
studies and further statistical analysis to identify 
risk factors for acquiring CPE and for worse 
outcomes would be relevant. As we show small 
numbers of patients treated for each treatment 
modality, these numbers do not allow us to make 




While KPC seems to be the most common 
carbapenemase found in Mediterranean 
countries, our hospital registered an important 
outbreak of OXA-48 isolates. This should warn 
us for the probable rise of these strains in the 
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next years. Patients at risk were elderly, had 
medical devices inserted or open wounds, had 
taken antibiotics in the prior 30 days or had had 
contact with medical institutions. This should 
make us rethink some of our practices in order 
to prevent new infections/colonizations. 
Case fatality rate is high (global case fatality 
rate of 32%), even in patients only considered 
colonized. Combination therapy and the 
rational use of new antimicrobial agents such as 
ceftazidime-avibactam lead to better outcomes. 
Regarding outbreaks, we hereby recommend 
permanent effective communication and 
multidisciplinary team work as some of the best 
strategies for tackling propagation. 
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